AI has designed candidate drugs for antibiotic-resistant infections and genetic diseases. But efforts to incorporate AI into the design of lipid nanoparticles (LNPs), the revolutionary delivery ...

Models will commoditize. Capabilities will converge. What will endure are the interfaces agents already rely on, and the data and execution capabilities behind them.

OpenAI's $110B funding includes AWS as the exclusive third-party distributor for the Frontier agent platform, introducing an ...